Combined First-Trimester PAPP-A and Free β-hCG Levels for the Early Diagnosis of Placenta Accreta Spectrum and Placenta Previa: A Case-Control Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136187 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vera Belousova und 10 weiteren Autor:innen. Beteiligte Einrichtung: I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia. Hauptthemen laut MEDLINE: Pregnancy-Associated Plasma Protein-A, Chorionic Gonadotropin, beta Subunit, Human, Pregnancy Trimester, First, Placenta Accreta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Placenta accreta spectrum (PAS) and placenta previa (PP) are severe obstetric disorders associated with high maternal and perinatal morbidity. Early diagnosis of both conditions remains challenging, particularly in cases with subtle imaging findings. This study was aimed to evaluate the diagnostic value of first-trimester maternal serum levels of pregnancy-associated plasma protein-A (PAPP-A) and free beta subunit of human chorionic gonadotropin (β-hCG) in predicting PAS and PP. In this retrospective case–control study, a total of 100 pregnant women were included: 36 with PAS, 32 with PP, and 32 healthy controls. Serum levels were measured at 11–136 weeks of gestation. Both biomarkers were significantly altered in pathological groups compared to controls: PAPP-A was lower in PP (3.04 [1.42–4.52] IU/L) and PAS (3.63 [2.51–5.39] IU/L) vs. controls (5.34 [3.72–8.41] IU/L; p < 0.001), while β-hCG was higher in PP (45.4 [40.1–54.9] IU/L) and PAS (51.4 [32.3–74.8] IU/L) vs. controls (33.5 [22.7–54.1] IU/L; p = 0.044 and p < 0.001, respectively). ROC analysis demonstrated that combined biomarker modeling improved diagnostic accuracy over single-marker use, with AUCs reaching 0.85 (sensitivity 85.2%, specificity 72%) for PAS and 0.88 (sensitivity 100%, specificity 72%) for PP. These findings support the integration of biochemical screening into first-trimester risk assessment protocols. Incorporating maternal serum biomarkers may enhance early identification of high-risk pregnancies, allow timely referral to specialized care, and reduce adverse outcomes. Further prospective studies are warranted to validate the utility of this dual-marker approach across diverse populations and clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
ORCID-Profile: Vera Belousova, Evdokiya Zarova, Svetlana Pesegova, Oxana Skorobogatova, Natalia Kireeva, Anna Maltseva
Zitieren
APA
Belousova, V., Ignatko, I., Bogomazova, I., Zarova, E., Pesegova, S., Samusevich, A., Kardanova, M., Skorobogatova, O., Kuzmina, T., Kireeva, N., & Maltseva, A. (2025). Combined First-Trimester PAPP-A and Free β-hCG Levels for the Early Diagnosis of Placenta Accreta Spectrum and Placenta Previa: A Case-Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136187
Vancouver
Belousova V, Ignatko I, Bogomazova I, Zarova E, Pesegova S, Samusevich A, et al. Combined First-Trimester PAPP-A and Free β-hCG Levels for the Early Diagnosis of Placenta Accreta Spectrum and Placenta Previa: A Case-Control Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136187
BibTeX
@article{Belousova2025,
author = {Belousova, Vera and Ignatko, Irina and Bogomazova, Irina and Zarova, Evdokiya and Pesegova, Svetlana and Samusevich, Anastasia and Kardanova, Madina and Skorobogatova, Oxana and Kuzmina, Tatiana and Kireeva, Natalia and Maltseva, Anna},
title = {Combined First-Trimester PAPP-A and Free β-hCG Levels for the Early Diagnosis of Placenta Accreta Spectrum and Placenta Previa: A Case-Control Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136187}
}
EUVIMED